药物基因组学检测：医学实践中的相关性：为什么有些患者的药物有效而有些患者的药物无效。
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.
机构信息
Department of Pharmacology, Division of Clinical Trials, College of Medicine, The Ohio State University, Columbus, USA.
出版信息
Cleve Clin J Med. 2011 Apr;78(4):243-57. doi: 10.3949/ccjm.78a.10145.
Abstract
Genetics may account for much of the variability in our patients' responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. It also discusses the future role of pharmacogenomic testing in medicine.
摘要
遗传学可能解释了我们的患者对药物治疗反应存在差异的很大一部分原因。本文为临床医生提供了关于药物基因组学检测的最新概述，讨论了与华法林（Coumadin）、氯吡格雷（Plavix）、他汀类药物、他莫昔芬（Nolvadex）、可待因和精神药物使用相关的新兴经过验证的检测的意义和局限性。本文还讨论了药物基因组学检测在医学中的未来作用。
相似文献
1
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.药物基因组学检测：医学实践中的相关性：为什么有些患者的药物有效而有些患者的药物无效。
Cleve Clin J Med. 2011 Apr;78(4):243-57. doi: 10.3949/ccjm.78a.10145.
2
Is personalized medicine a dream or a reality?个性化医学：是梦想还是现实？
Crit Rev Clin Lab Sci. 2015 Feb;52(1):1-11. doi: 10.3109/10408363.2014.950407. Epub 2014 Sep 2.
3
Clinical pharmacogenomics of warfarin and clopidogrel.华法林和氯吡格雷的临床药物基因组学
J Pharm Pract. 2012 Aug;25(4):428-38. doi: 10.1177/0897190012448310. Epub 2012 Jun 6.
4
Cardiovascular Pharmacogenomics--Implications for Patients With CKD.心血管药物基因组学——对慢性肾脏病患者的影响
Adv Chronic Kidney Dis. 2016 Mar;23(2):82-90. doi: 10.1053/j.ackd.2015.12.001.
5
PHARMACOGENOMIC DETERMINANTS OF RESPONSE TO CARDIOVASCULAR DRUGS.心血管药物反应的药物基因组学决定因素
Med Pregl. 2015 Jul-Aug;68(7-8):259-65. doi: 10.2298/mpns1508259s.
6
Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.华法林或氯吡格雷患者进行药物基因检测的意义。
Curr Neurol Neurosci Rep. 2011 Feb;11(1):52-60. doi: 10.1007/s11910-010-0157-8.
7
Lipophilic statins do not affect the antiplatelet potency of clopidogrel.亲脂性他汀类药物不影响氯吡格雷的抗血小板效力。
Platelets. 2005 May-Jun;16(3-4):225-6. doi: 10.1080/09537100500124525.
8
Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.药物遗传学检测：对氯吡格雷和华法林心血管治疗的影响
Cardiovasc Ther. 2010 Jun;28(3):135-8. doi: 10.1111/j.1755-5922.2010.00176.x.
9
Clopidogrel-statin interaction: a mountain or a mole hill?氯吡格雷与他汀类药物的相互作用：小题大做还是确有其事？
Am Heart J. 2006 Aug;152(2):200-3. doi: 10.1016/j.ahj.2006.01.001.
10
Possible mechanisms of drug-induced aspirin and clopidogrel resistance.药物诱导的阿司匹林和氯吡格雷抵抗的可能机制。
J Thromb Thrombolysis. 2006 Oct;22(2):139-50. doi: 10.1007/s11239-006-8670-y.
引用本文的文献
1
Dual Versus Mono Antiplatelet Therapy in Patients with Acute Mild-to-Moderate Stroke: A Multicentre Perspective Cohort Study.急性轻至中度卒中患者的双联抗血小板治疗与单联抗血小板治疗：一项多中心前瞻性队列研究
Cardiovasc Drugs Ther. 2024 Dec;38(6):1259-1270. doi: 10.1007/s10557-023-07468-7. Epub 2023 Jun 13.
2
Epigenetic Mechanisms Contribute to Intraindividual Variations of Drug Metabolism Mediated by Cytochrome P450 Enzymes.表观遗传机制导致细胞色素 P450 酶介导的药物代谢的个体内差异。
Drug Metab Dispos. 2023 Jun;51(6):672-684. doi: 10.1124/dmd.122.001007. Epub 2023 Mar 27.
3
Non-genetic physicians' knowledge, attitudes and behavior towards medical genetics.非遗传科医生对医学遗传学的知识、态度和行为。
Wien Klin Wochenschr. 2024 Mar;136(5-6):137-145. doi: 10.1007/s00508-023-02152-0. Epub 2023 Feb 10.
4
Nation-Wide Survey Assessing the Knowledge and Attitudes of Romanian Pharmacists Concerning Pharmacogenetics.评估罗马尼亚药剂师对药物遗传学的知识和态度的全国性调查。
Front Pharmacol. 2022 Jul 1;13:952562. doi: 10.3389/fphar.2022.952562. eCollection 2022.
5
Biomarker and Companion Diagnostics-A Review of Medicinal Products Approved by the European Medicines Agency.生物标志物与伴随诊断——欧洲药品管理局批准的医药产品综述
Front Med (Lausanne). 2021 Nov 1;8:753187. doi: 10.3389/fmed.2021.753187. eCollection 2021.
6
Pharmacogenomics In Pharmacy Practice: Current Perspectives.药学实践中的药物基因组学：当前观点
Integr Pharm Res Pract. 2019 Nov 8;8:97-104. doi: 10.2147/IPRP.S180154. eCollection 2019.
7
Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.美国和匈牙利药品标签中药物基因组生物标志物信息的差异：从医疗从业者的角度看实施情况。
Pharmacogenomics J. 2020 Jun;20(3):380-387. doi: 10.1038/s41397-019-0123-z. Epub 2019 Dec 2.
8
The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review.CYP2C19 和非遗传因素对中东和北非地区氯吡格雷反应性的影响：系统评价。
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619875520. doi: 10.1177/1076029619875520.
9
Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.基于药物基因组学的急性缺血性小卒中和短暂性脑缺血发作的个体化抗血小板治疗：一项随机对照试验的研究方案。
BMJ Open. 2019 May 22;9(5):e028595. doi: 10.1136/bmjopen-2018-028595.
10
Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow.将下一代测序技术整合到临床药物基因组学工作流程中。
Front Pharmacol. 2019 Apr 5;10:384. doi: 10.3389/fphar.2019.00384. eCollection 2019.
本文引用的文献
1
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.CYP2C19 基因型对氯吡格雷治疗结局的影响。
N Engl J Med. 2010 Oct 28;363(18):1704-14. doi: 10.1056/NEJMoa1008410. Epub 2010 Aug 29.
2
ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.美国心脏病学会基金会/美国心脏协会氯吡格雷临床警报：应对美国食品药品监督管理局“黑框警告”：美国心脏病学会基金会临床专家共识文件特别工作组和美国心脏协会的报告
Circulation. 2010 Aug 3;122(5):537-57. doi: 10.1161/CIR.0b013e3181ee08ed. Epub 2010 Jun 28.
3
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.CYP3A4 内含子多态性影响肝表达和对他汀类药物的反应。
Pharmacogenomics J. 2011 Aug;11(4):274-86. doi: 10.1038/tpj.2010.28. Epub 2010 Apr 13.
4
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).华法林基因分型降低了住院率，这是 MM-WES（美科梅奥华法林有效性研究）的结果。
J Am Coll Cardiol. 2010 Jun 22;55(25):2804-12. doi: 10.1016/j.jacc.2010.03.009. Epub 2010 Apr 8.
5
Measuring cis-acting regulatory variants genome-wide: new insights into expression genetics and disease susceptibility.全基因组范围内测量顺式作用调控变体：对表达遗传学和疾病易感性的新见解。
Genome Med. 2009 Dec 22;1(12):116. doi: 10.1186/gm116.
6
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.复合功能遗传和共用药 CYP2D6 活性评分预测乳腺癌患者他莫昔芬药物暴露。
J Clin Pharmacol. 2010 Apr;50(4):450-8. doi: 10.1177/0091270009359182. Epub 2010 Jan 15.
7
Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.基因分型指导心房颤动患者华法林剂量调整的成本效益分析
Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):429-36. doi: 10.1161/CIRCOUTCOMES.108.808592. Epub 2009 Jul 21.
8
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.评估华法林药物基因组学检测的获益、风险和成本的政策模型。
Pharmacoeconomics. 2010;28(1):61-74. doi: 10.2165/11318240-000000000-00000.
9
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.SLCO1B1（OATP1B1）基因多态性对他汀类药物治疗反应的影响。
Pharmacogenomics J. 2010 Feb;10(1):1-11. doi: 10.1038/tpj.2009.54. Epub 2009 Nov 3.
10
Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.母亲接受可待因治疗对母乳喂养新生儿的风险：一项定量机制建模研究。
Clin Pharmacol Ther. 2009 Dec;86(6):634-43. doi: 10.1038/clpt.2009.151. Epub 2009 Aug 26.
Zotero 插件